OAC Share Price | Hims & Hers Health, Inc. Stock Analysis & Recommendation

Q: How big is Hims & Hers Health, Inc.?

Market Cap: As of Jun 18, Hims & Hers Health, Inc. has a market capitalization of 13,259.78 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Hims & Hers Health, Inc. reported net sales of 1,784.36 million and a net profit of 164.39 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 476.72 million and total assets of 724.81 million.

Q: What does Hims & Hers Health, Inc. do?

Overview: Hims & Hers Health, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.Financial Snapshot: Most recent Net Sales: 586 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 49 Million (Quarterly Results - Mar 2025) Market-cap: USD 13,259.78 Million (Small Cap)Key Metrics: P/E: 74.00 Dividend Yield: 0.00% Debt Equity: -0.58 Return on Equity: 30.96% Price to Book: 24.14Contact Details: Registrar Address: Not available.

Q: Is Hims & Hers Health, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Hims & Hers Health, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The Bollinger Bands show a bullish stance on the weekly and mildly bullish on the monthly. Daily moving averages are bullish, supporting a positive short-term outlook. However, the KST is mildly bearish weekly and bullish monthly, and the Dow Theory indicates no trend in both weekly and monthly views. In terms of performance, the company has significantly outperformed the S&P 500 over the longer terms, with a year-to-date return of 126.34% compared to the S&P 500's 11.41%, and a one-year return of 192.83% against 13.36%. Overall, the current technical stance is mildly bullish, with strength derived from daily moving averages and the monthly MACD.

Q: Is Hims & Hers Health, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a PEG ratio of 0.01, indicating potential growth relative to its price.In comparison to peers, Hims & Hers has a P/E ratio that is higher than Addus HomeCare Corp. at 22.05 and significantly higher than Guardant Health, Inc., which has a negative P/E of -17.69. Despite the high valuation ratios, the company's strong ROCE of 50.18% and ROE of 30.96% suggest robust profitability. Over the past year, Hims & Hers has outperformed the S&P 500 with a return of 126.67% compared to the index's 16.90%, reinforcing its favorable valuation outlook.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

32.96 M

Shareholding (Dec 2025)

FII

11.80%

Held by 192 FIIs

DII

31.17%

Held by 77 DIIs

Promoter

4.76%

How big is Hims & Hers Health, Inc.?

22-Jun-2025

As of Jun 18, Hims & Hers Health, Inc. has a market capitalization of $13.26 billion, with net sales of $1.78 billion and a net profit of $164.39 million over the last four quarters. The company reported shareholder's funds of $476.72 million and total assets of $724.81 million as of Dec 24.

View full answer

What does Hims & Hers Health, Inc. do?

22-Jun-2025

Hims & Hers Health, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $586 million and a net profit of $49 million. Key metrics include a P/E ratio of 74.00 and a return on equity of 30.96%.

View full answer

Is Hims & Hers Health, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Hims & Hers Health, Inc. shows a mildly bullish trend with mixed technical signals, outperforming the S&P 500 significantly year-to-date and over the past year.

View full answer

Is Hims & Hers Health, Inc. overvalued or undervalued?

28-Oct-2025

As of October 24, 2025, Hims & Hers Health, Inc. is fairly valued with a P/E ratio of 74 and strong profitability metrics, having outperformed the S&P 500 with a 126.67% return over the past year.

View full answer

Compare Hims & Hers Health, Inc. with Similar Stocks

Addus HomeCare Corp.U.S. Physical Therapy, Inc.NeoGenomics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROE of 6.19%

The company has been able to generate a Return on Equity (avg) of 6.19% signifying low profitability per unit of shareholders funds

The company has declared Positive results for the last 13 consecutive quarters

With ROE of 30.96%, it has a fair valuation with a 22.96 Price to Book Value

Consistent Returns over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5,671 Million (Small Cap)

P/E

36.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.59

Return on Equity

27.23%

Price to Book

9.76

Revenue and Profits:

Net Sales:

618 Million

(Quarterly Results - Dec 2025)

Net Profit:

21 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-36.67%

6 Months

-60.82%

1 Year

-30.07%

2 Years

40.43%

3 Years

126.08%

4 Years

331.76%

5 Years

37.54%

Hims & Hers Health, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

366.61%

EBIT Growth (5y)

115.69%

EBIT to Interest (avg)

-19.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.58

Sales to Capital Employed (avg)

2.47

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

10.04%

ROE (avg)

6.19%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

9.76

EV to EBIT

45.64

EV to EBITDA

34.52

EV to Capital Employed

6.50

EV to Sales

2.72

PEG Ratio

0.63

Dividend Yield

ROCE (Latest)

14.24%

ROE (Latest)

27.23%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 88 Schemes (52.24%)

Foreign Institutions

Held by 192 Foreign Institutions (11.8%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 28.41% vs 95.09% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -20.77% vs 2,066.67% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "617.80",
          "val2": "481.10",
          "chgp": "28.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "30.70",
          "val2": "28.80",
          "chgp": "6.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "-4.20",
          "chgp": "85.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "20.60",
          "val2": "26.00",
          "chgp": "-20.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.50%",
          "val2": "47.30%",
          "chgp": "-2.68%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 59.00% vs 69.32% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 1.90% vs 636.17% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,347.60",
          "val2": "1,476.50",
          "chgp": "59.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "176.20",
          "val2": "85.10",
          "chgp": "107.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-20.90",
          "val2": "-6.10",
          "chgp": "-242.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "128.40",
          "val2": "126.00",
          "chgp": "1.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "51.80%",
          "val2": "46.10%",
          "chgp": "0.57%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

617.80

481.10

28.41%

Operating Profit (PBDIT) excl Other Income

30.70

28.80

6.60%

Interest

0.00

Exceptional Items

-0.60

-4.20

85.71%

Consolidate Net Profit

20.60

26.00

-20.77%

Operating Profit Margin (Excl OI)

20.50%

47.30%

-2.68%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 28.41% vs 95.09% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -20.77% vs 2,066.67% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

2,347.60

1,476.50

59.00%

Operating Profit (PBDIT) excl Other Income

176.20

85.10

107.05%

Interest

0.00

Exceptional Items

-20.90

-6.10

-242.62%

Consolidate Net Profit

128.40

126.00

1.90%

Operating Profit Margin (Excl OI)

51.80%

46.10%

0.57%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 59.00% vs 69.32% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 1.90% vs 636.17% in Dec 2024

All Annual Results

Company CV

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available